Product Information
BIKTARVY 30-120-15 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $136.6550 per EA under NDC 61958250501. Its NADAC has been published 124 times since May 22, 2024.
FDA first approved this application on Feb 7, 2018.
BIKTARVY 30-120-15 MG TABLET
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarateStrength
30; 120; 15 mg/1; mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958250501
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA210251FDA Approved
2/7/2018
On Market Since
10/7/2021
Pharmacological Classes
Price Statistics
The NADAC for BIKTARVY 30-120-15 MG TABLET has been published 124 times since May 22, 2024, and over the history we have for it it has risen 6.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $136.6550 per EA |
|---|---|
| All-time high | $136.7316 (Apr 15, 2026) |
| All-time low | $128.6639 (May 22, 2024) |
| 52-week high | $136.7316 |
| 52-week low | $136.5043 |
| Median price | $136.5043 |
| Average price | $134.4383 |
| Largest weekly change | +5.9% (Jan 15, 2025) |
| Weeks tracked | 124 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BIKTARVY 30-120-15 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BIKTARVY 30-120-15 MG TABLET, manufactured by Gilead Sciences, Inc., is $136.6550 per EA (NDC 61958250501), effective Sep 30, 2026.
How has the price of BIKTARVY 30-120-15 MG TABLET changed over time?
Over the history we have for it, the NADAC for BIKTARVY 30-120-15 MG TABLET has risen 6.2%. It has been tracked across 124 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for BIKTARVY 30-120-15 MG TABLET?
Since May 22, 2024, the NADAC for BIKTARVY 30-120-15 MG TABLET has ranged from a low of $128.6639 (May 22, 2024) to a high of $136.7316 (Apr 15, 2026), with a median of $136.5043 per EA.
Are there cheaper alternatives to BIKTARVY 30-120-15 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of BIKTARVY 30-120-15 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BIKTARVY 30-120-15 MG TABLET?
BIKTARVY 30-120-15 MG TABLET (NDC 61958250501) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.